However, the applicability of this approach remains limited to tumors with sufficient Trop-2 expression, and its efficacy in broader MDR contexts, especially in luminal breast cancer models lacking Trop-2, such as MCF-7, has not been established. This evidence concerns the gene TACSTD2 and breast cancer.